Application of cord blood-derived platelet-rich plasma in the treatment of diseases

• Published in: Journal of international medical research 2024-07, Vol.52 (7), p.3000605241263729
• Main Authors: Tang, Yukuan, Li, Yongsheng, Chen, Hanwei, Huang, Yuyang, Huang, Chen, Wei, Wei
• Format: Article
• Language: English
• Subjects: Fetal Blood - cytology; Humans; Narrative Review; Platelet-Rich Plasma
• ISSN: 0300-0605; 1473-2300; 1473-2300
• DOI: 10.1177/03000605241263729

Platelet-rich plasma (PRP), a blood product containing high concentrations of platelets, has been increasingly used for the treatment of a number of diseases because of its anti-inflammatory and regenerative properties. PRP is generally obtained from the patient’s own peripheral blood when used in clinical applications, but allogeneic PRP extracted from umbilical cord blood has also attracted attention due to its unique advantages. The main purpose of this narrative review was to summarize the research and clinical application of cord blood-derived PRP (CB-PRP) in the treatment of diseases up to April 2024. This review also discusses the differences between CB-PRP and autologous PRP (A-PRP). A thorough search of PubMed® and Clinicaltrials.gov identified 13 articles and four clinical trials. To date, CB-PRP has been primarily studied in the fields of orthopaedics, dermatology, neurology, obstetrics/gynaecology and ophthalmology. This is likely to be because this research is relatively novel. Considering the differences between the characteristics of A-PRP and CB-PRP, it is thought that CB-PRP might hold more promise for broader applications in the future.